Brief: Xintela Unit Selects Targ9 As Drug Candidate
05/04/2022 12:58
April 5 (Reuters) - Xintela AB XINT.ST :
* TARGINTA SELECTS ADC-ANTIBODY TARG9 AS DRUG CANDIDATE
* CANDIDATE, BEING DEVELOPED AGAINST TRIPLE-NEGATIVE BREAST
CANCER
AND GLIOBLASTOMA, NOW ENTERS PRECLINICAL DEVELOPMENT
Source text for Eikon: ID:nMFN5nj3nD
Further company coverage: XINT.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))